Exact Mass: 990.4406531999999

Exact Mass Matches: 990.4406531999999

Found 58 metabolites which its exact mass value is equals to given mass value 990.4406531999999, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Pengitoxin

5-{[4-(acetyloxy)-5-{[4-(acetyloxy)-5-{[4,5-bis(acetyloxy)-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate

C51H74O19 (990.4824054000001)


D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D000113 - Acetyldigoxins

   

PGP(22:5(4Z,7Z,10Z,13Z,16Z)/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(22:5(4Z,7Z,10Z,13Z,16Z)/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(22:5(4Z,7Z,10Z,13Z,16Z)/6 keto-PGF1alpha), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/22:5(4Z,7Z,10Z,13Z,16Z))

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(6 keto-PGF1alpha/22:5(4Z,7Z,10Z,13Z,16Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(22:5(4Z,7Z,10Z,13Z,16Z)/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(22:5(4Z,7Z,10Z,13Z,16Z)/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(22:5(4Z,7Z,10Z,13Z,16Z)/TXB2), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/22:5(4Z,7Z,10Z,13Z,16Z))

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(TXB2/22:5(4Z,7Z,10Z,13Z,16Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(22:5(7Z,10Z,13Z,16Z,19Z)/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(22:5(7Z,10Z,13Z,16Z,19Z)/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(22:5(7Z,10Z,13Z,16Z,19Z)/6 keto-PGF1alpha), in particular, consists of one chain of one 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/22:5(7Z,10Z,13Z,16Z,19Z))

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(6 keto-PGF1alpha/22:5(7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(22:5(7Z,10Z,13Z,16Z,19Z)/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(22:5(7Z,10Z,13Z,16Z,19Z)/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(22:5(7Z,10Z,13Z,16Z,19Z)/TXB2), in particular, consists of one chain of one 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/22:5(7Z,10Z,13Z,16Z,19Z))

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H80O17P2 (990.4870490000002)


PGP(TXB2/22:5(7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PIP(16:2(9Z,12Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

{[(1R,3S)-3-({[(2R)-2-{[(5Z,7R,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(16:2(9Z,12Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(16:2(9Z,12Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:2(9Z,12Z))

{[(1R,3S)-3-({[(2R)-3-{[(5Z,7S,8E,10Z,13Z,15E,17R,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:2(9Z,12Z)), in particular, consists of one chain of Resolvin D5 at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(16:2(9Z,12Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

{[(1R,3S)-3-({[(2R)-2-{[(4Z,7Z,10R,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(16:2(9Z,12Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(16:2(9Z,12Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of Protectin DX at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:2(9Z,12Z))

{[(1R,3S)-3-({[(2R)-3-{[(4Z,7Z,10S,11E,13Z,15E,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:2(9Z,12Z)), in particular, consists of one chain of Protectin DX at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(18:3(6Z,9Z,12Z)/PGJ2)

{[(1S,6R,12Z,15S,19R,20R,21R,22R,23S,24R)-3,20,22,23,24-pentahydroxy-19-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-{[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]methyl}-3,8,18-trioxo-2,4,7-trioxa-3lambda5-phosphabicyclo[13.6.3]tetracosa-12,16-dien-21-yl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(18:3(6Z,9Z,12Z)/PGJ2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(18:3(6Z,9Z,12Z)/PGJ2), in particular, consists of one chain of 6Z,9Z,12Z-octadecatrienoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(PGJ2/18:3(6Z,9Z,12Z))

{[(1S,6R,13Z,16S,20R,21R,22R,23R,24S,25R)-3,21,23,24,25-pentahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]-3,9,19-trioxo-2,4,8-trioxa-3lambda5-phosphabicyclo[14.6.3]pentacosa-13,17-dien-22-yl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(PGJ2/18:3(6Z,9Z,12Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(PGJ2/18:3(6Z,9Z,12Z)), in particular, consists of one chain of Prostaglandin J2 at the C-1 position and one chain of 6Z,9Z,12Z-octadecatrienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(18:3(9Z,12Z,15Z)/PGJ2)

{[(1S,6R,12Z,15S,19R,20R,21R,22R,23S,24R)-3,20,22,23,24-pentahydroxy-19-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-{[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]methyl}-3,8,18-trioxo-2,4,7-trioxa-3lambda5-phosphabicyclo[13.6.3]tetracosa-12,16-dien-21-yl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(18:3(9Z,12Z,15Z)/PGJ2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(18:3(9Z,12Z,15Z)/PGJ2), in particular, consists of one chain of 9Z,12Z,15Z-octadecatrienoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(PGJ2/18:3(9Z,12Z,15Z))

{[(1S,6R,13Z,16S,20R,21R,22R,23R,24S,25R)-3,21,23,24,25-pentahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]-3,9,19-trioxo-2,4,8-trioxa-3lambda5-phosphabicyclo[14.6.3]pentacosa-13,17-dien-22-yl]oxy}phosphonic acid

C47H76O18P2 (990.4506656)


PIP(PGJ2/18:3(9Z,12Z,15Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(PGJ2/18:3(9Z,12Z,15Z)), in particular, consists of one chain of Prostaglandin J2 at the C-1 position and one chain of 9Z,12Z,15Z-octadecatrienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   

Pennogenin-hexaacetyl-3-O-??-L-rhamnopyranosyl(1鈥樏傗垎2)-??-D-glucopyranoside

Pennogenin-hexaacetyl-3-O-??-L-rhamnopyranosyl(1鈥樏傗垎2)-??-D-glucopyranoside

C51H74O19 (990.4824054000001)


   
   

Acetyl-GRP (20-27) (human, porcine, canine)

Acetyl-GRP (20-27) (human, porcine, canine)

C46H66N14O9S (990.4857666000001)


   
   
   
   
   

PGP(22:5(4Z,7Z,10Z,13Z,16Z)/6 keto-PGF1alpha)

PGP(22:5(4Z,7Z,10Z,13Z,16Z)/6 keto-PGF1alpha)

C48H80O17P2 (990.4870490000002)


   

PGP(6 keto-PGF1alpha/22:5(4Z,7Z,10Z,13Z,16Z))

PGP(6 keto-PGF1alpha/22:5(4Z,7Z,10Z,13Z,16Z))

C48H80O17P2 (990.4870490000002)


   

PGP(22:5(7Z,10Z,13Z,16Z,19Z)/6 keto-PGF1alpha)

PGP(22:5(7Z,10Z,13Z,16Z,19Z)/6 keto-PGF1alpha)

C48H80O17P2 (990.4870490000002)


   

PGP(6 keto-PGF1alpha/22:5(7Z,10Z,13Z,16Z,19Z))

PGP(6 keto-PGF1alpha/22:5(7Z,10Z,13Z,16Z,19Z))

C48H80O17P2 (990.4870490000002)


   

PIP(18:3(6Z,9Z,12Z)/PGJ2)

PIP(18:3(6Z,9Z,12Z)/PGJ2)

C47H76O18P2 (990.4506656)


   

PIP(PGJ2/18:3(6Z,9Z,12Z))

PIP(PGJ2/18:3(6Z,9Z,12Z))

C47H76O18P2 (990.4506656)


   

PIP(18:3(9Z,12Z,15Z)/PGJ2)

PIP(18:3(9Z,12Z,15Z)/PGJ2)

C47H76O18P2 (990.4506656)


   

PIP(PGJ2/18:3(9Z,12Z,15Z))

PIP(PGJ2/18:3(9Z,12Z,15Z))

C47H76O18P2 (990.4506656)


   

PIP(16:2(9Z,12Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

PIP(16:2(9Z,12Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C47H76O18P2 (990.4506656)


   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:2(9Z,12Z))

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:2(9Z,12Z))

C47H76O18P2 (990.4506656)


   

PIP(16:2(9Z,12Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

PIP(16:2(9Z,12Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C47H76O18P2 (990.4506656)


   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:2(9Z,12Z))

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:2(9Z,12Z))

C47H76O18P2 (990.4506656)


   
   

8-(Methoxycarbonyl)octyl 2-(acetylamino)-3-O-alpha-L-fucopyranosyl-4-O-[3-O-(N-acetyl-alpha-neuraminosyl)-beta-D-galactopyranosyl]-2-deoxy-beta-D-glucopyranoside

8-(Methoxycarbonyl)octyl 2-(acetylamino)-3-O-alpha-L-fucopyranosyl-4-O-[3-O-(N-acetyl-alpha-neuraminosyl)-beta-D-galactopyranosyl]-2-deoxy-beta-D-glucopyranoside

C41H70N2O25 (990.4267450000001)


   

(2S,4S,5R,6R)-5-acetamido-2-[(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-(9-methoxy-9-oxononoxy)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

(2S,4S,5R,6R)-5-acetamido-2-[(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-(9-methoxy-9-oxononoxy)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

C41H70N2O25 (990.4267450000001)


   

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(7E,9E,11Z,13E,15E,17Z)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (7E,9E,11E,13E,15Z,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(7E,9E,11Z,13E,15E,17Z)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (7E,9E,11E,13E,15Z,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

C51H76O15P2 (990.4659206)


   
   

PIP2(34:4)

PIP2(16:1_18:3)

C43H77O19P3 (990.4271682)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

Spinorphin (TFA)

Spinorphin (TFA)

C47H65F3N8O12 (990.4673806)


Spinorphin TFA is an inhibitor of enkephalin-degrading enzymes. Spinorphin inhibits aminopeptidase, dipeptidyl aminopeptidase III, angiotensin-converting enzyme and enkephalinase. Spinorphin possesses an antinociceptive effect[1].

   

11-{[3-({3,4-dihydroxy-5-[(3-hydroxy-6-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

11-{[3-({3,4-dihydroxy-5-[(3-hydroxy-6-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

C44H78O24 (990.4882788)


   

3-{[(2r,10r,13r,21r,24r,32r)-21,32-bis[(3-carboxy-1-hydroxypropylidene)amino]-5,16,27-trihydroxy-2,13,24-trimethyl-4,11,15,22,26,33-hexaoxo-1,12,23-trioxa-5,16,27-triazacyclotritriacontan-10-yl]-c-hydroxycarbonimidoyl}propanoic acid

3-{[(2r,10r,13r,21r,24r,32r)-21,32-bis[(3-carboxy-1-hydroxypropylidene)amino]-5,16,27-trihydroxy-2,13,24-trimethyl-4,11,15,22,26,33-hexaoxo-1,12,23-trioxa-5,16,27-triazacyclotritriacontan-10-yl]-c-hydroxycarbonimidoyl}propanoic acid

C42H66N6O21 (990.4280826000002)


   

4a,6,8,12b-tetrahydroxy-9-{5-hydroxy-4-[(4-hydroxy-5-{[5-(c-hydroxycarbonimidoylamino)-6-methyloxan-2-yl]oxy}-4,6-dimethyloxan-2-yl)oxy]-6-methyloxan-2-yl}-1-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-3-methyl-7,12-dioxo-1,4,5,6-tetrahydrotetraphen-5-yl acetate

4a,6,8,12b-tetrahydroxy-9-{5-hydroxy-4-[(4-hydroxy-5-{[5-(c-hydroxycarbonimidoylamino)-6-methyloxan-2-yl]oxy}-4,6-dimethyloxan-2-yl)oxy]-6-methyloxan-2-yl}-1-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-3-methyl-7,12-dioxo-1,4,5,6-tetrahydrotetraphen-5-yl acetate

C48H66N2O20 (990.4208716)


   

(1s,4as,5s,6s,12bs)-4a,6,8,12b-tetrahydroxy-1-{[(2s,4r,5r,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-9-[(2r,4r,5r,6r)-5-hydroxy-4-{[(2s,4s,5r,6r)-4-hydroxy-5-{[(2s,5s,6r)-5-(c-hydroxycarbonimidoylamino)-6-methyloxan-2-yl]oxy}-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-7,12-dioxo-1,4,5,6-tetrahydrotetraphen-5-yl acetate

(1s,4as,5s,6s,12bs)-4a,6,8,12b-tetrahydroxy-1-{[(2s,4r,5r,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-9-[(2r,4r,5r,6r)-5-hydroxy-4-{[(2s,4s,5r,6r)-4-hydroxy-5-{[(2s,5s,6r)-5-(c-hydroxycarbonimidoylamino)-6-methyloxan-2-yl]oxy}-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-7,12-dioxo-1,4,5,6-tetrahydrotetraphen-5-yl acetate

C48H66N2O20 (990.4208716)


   

3-({2-amino-6-[({8,9-dihydroxy-5-[3-(c-hydroxycarbonimidoyl)propanamido]-1h,2h,3h,4h,4ah-pyrimido[1,2-a]quinolin-1-yl}(hydroxy)methylidene)amino]-1-hydroxyhexylidene}amino)-2-hydroxy-3-[(1-{[2-hydroxy-1-({1-[(1-hydroxy-2-oxopiperidin-3-yl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]propanoic acid

3-({2-amino-6-[({8,9-dihydroxy-5-[3-(c-hydroxycarbonimidoyl)propanamido]-1h,2h,3h,4h,4ah-pyrimido[1,2-a]quinolin-1-yl}(hydroxy)methylidene)amino]-1-hydroxyhexylidene}amino)-2-hydroxy-3-[(1-{[2-hydroxy-1-({1-[(1-hydroxy-2-oxopiperidin-3-yl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]propanoic acid

C42H62N12O16 (990.4406531999999)


   

(11s)-11-{[(2r,3r,4s,5r,6r)-3-{[(2s,3r,4s,5r,6s)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6s)-3-hydroxy-6-methyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

(11s)-11-{[(2r,3r,4s,5r,6r)-3-{[(2s,3r,4s,5r,6s)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6s)-3-hydroxy-6-methyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

C44H78O24 (990.4882788)


   

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-({[(2s,3r,4s,5s,6r)-3-(3,4-dimethoxybenzoyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-8-hydroxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-({[(2s,3r,4s,5s,6r)-3-(3,4-dimethoxybenzoyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-8-hydroxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C51H74O19 (990.4824054000001)


   

(3r)-3-amino-3-{[(1s)-1-{[(2r,3r)-1-[(2s)-n-[(2s)-2-amino-6-{[(8,9-dihydroxy-5-{[1-hydroxy-3-(c-hydroxycarbonimidoyl)propylidene]amino}-1h,2h,3h,5h,6h-pyrimido[1,2-a]quinolin-1-yl)(hydroxy)methylidene]amino}hexanoyl]-2-{[(3r)-1-hydroxy-2-oxopiperidin-3-yl]amino}propanamido]-3-hydroxy-1-oxobutan-2-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}-2-hydroxypropanoic acid

(3r)-3-amino-3-{[(1s)-1-{[(2r,3r)-1-[(2s)-n-[(2s)-2-amino-6-{[(8,9-dihydroxy-5-{[1-hydroxy-3-(c-hydroxycarbonimidoyl)propylidene]amino}-1h,2h,3h,5h,6h-pyrimido[1,2-a]quinolin-1-yl)(hydroxy)methylidene]amino}hexanoyl]-2-{[(3r)-1-hydroxy-2-oxopiperidin-3-yl]amino}propanamido]-3-hydroxy-1-oxobutan-2-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}-2-hydroxypropanoic acid

C42H62N12O16 (990.4406531999999)


   

3-({21,32-bis[(3-carboxy-1-hydroxypropylidene)amino]-5,16,27-trihydroxy-2,13,24-trimethyl-4,11,15,22,26,33-hexaoxo-1,12,23-trioxa-5,16,27-triazacyclotritriacontan-10-yl}-c-hydroxycarbonimidoyl)propanoic acid

3-({21,32-bis[(3-carboxy-1-hydroxypropylidene)amino]-5,16,27-trihydroxy-2,13,24-trimethyl-4,11,15,22,26,33-hexaoxo-1,12,23-trioxa-5,16,27-triazacyclotritriacontan-10-yl}-c-hydroxycarbonimidoyl)propanoic acid

C42H66N6O21 (990.4280826000002)


   

11-{[3-({6-[({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)methyl]-4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

11-{[3-({6-[({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)methyl]-4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}tetradecanoic acid

C44H78O24 (990.4882788)


   

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-({[(2s,3r,4s,5r,6r)-3-(3,4-dimethoxybenzoyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-8-hydroxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-({[(2s,3r,4s,5r,6r)-3-(3,4-dimethoxybenzoyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-8-hydroxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C51H74O19 (990.4824054000001)


   

(2r,3r)-3-{[(2s)-6-({[(1r,4as)-8,9-dihydroxy-5-[3-(c-hydroxycarbonimidoyl)propanamido]-1h,2h,3h,4h,4ah-pyrimido[1,2-a]quinolin-1-yl](hydroxy)methylidene}amino)-2-amino-1-hydroxyhexylidene]amino}-2-hydroxy-3-{[(1s)-1-{[(1r,2r)-2-hydroxy-1-{[(1s)-1-{[(3r)-1-hydroxy-2-oxopiperidin-3-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}propanoic acid

(2r,3r)-3-{[(2s)-6-({[(1r,4as)-8,9-dihydroxy-5-[3-(c-hydroxycarbonimidoyl)propanamido]-1h,2h,3h,4h,4ah-pyrimido[1,2-a]quinolin-1-yl](hydroxy)methylidene}amino)-2-amino-1-hydroxyhexylidene]amino}-2-hydroxy-3-{[(1s)-1-{[(1r,2r)-2-hydroxy-1-{[(1s)-1-{[(3r)-1-hydroxy-2-oxopiperidin-3-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}propanoic acid

C42H62N12O16 (990.4406531999999)